MDS & Myeloproliferative Neoplasms

MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

Transplant or No Transplant for Older, Fit Patients With MDS?

Hematopoietic cell transplantation (HCT) with reduced-intensity conditioning improved overall survival (OS) in older patients with advanced myelodysplastic syndromes (MDS), compared with OS in patients...

An MRD-Guided Azacitidine Treatment Strategy Delays Hematologic Relapse in MDS and AML

According to results from the phase II RELAZA2 trial, minimal residual disease (MRD)–guided treatment with the hypomethylating agent azacitidine delayed hematologic relapse in patients...

Luspatercept Reduces the Need for Transfusions in Patients With Beta Thalassemia and MDS

In two separate phase III trials presented at the 2018 ASH Annual Meeting, luspatercept, a first-in-class recombinant fusion protein, was found to be safe...

Algorithm Built on Big Data Improves Prognostic Accuracy Over Existing MDS Models

Using machine learning, researchers were able to develop a prognostic model that predicted survival among patients with myelodysplastic syndromes (MDS) and was more accurate...

How I Treat in Brief: Using Molecular Genetic Tests to Evaluate Myelodysplastic Syndromes

David P. Steensma, MD, of Dana-Farber Cancer Institute and Harvard Medical School in Boston, discussed how to use results from molecular genetic tests in...
WIB_icon

No Benefit With Adding Eltrombopag to Azacitidine in Patients With Higher-Risk MDS

In the phase III SUPPORT trial, researchers tested the hypothesis that concomitant administration of the thrombopoietin receptor agonist eltrombopag could ameliorate the thrombocytopenic effects...

Researchers Identify Genetic Prognostic Predictors in Myeloproliferative Neoplasms

A team of European and American researchers have identified and characterized associations between specific genetic mutations and prognosis in patients with myeloproliferative neoplasms (MPNs),...

Post-Transplant Gene Mutations Predict Risk for MDS Progression

Sequencing bone marrow samples early after patients with myelodysplastic syndromes (MDS) have undergone allogeneic hematopoietic cell transplantation (AHCT) could help identify patients who are...

Demystifying Epigenetics in Hematology

In the early 20th century, German researcher Theodor Boveri described the basic tenets of tumor biology: Cells can turn cancerous when they lose the...

Can Cytarabine Prevent Progression to Myeloid Leukemia in Children With Down Syndrome and Transient...

In pediatric patients with Down syndrome (DS) and transient myeloproliferative disorder (TMD), treatment with low-dose cytarabine lowered early mortality risk, compared with historical controls,...
Advertisement

Current Issue

February 2019, Volume 5, Issue 3

This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.